Arvinas, Inc. (ARVN) vs Eupraxia Pharmaceuticals Inc. (EPRX)

Arvinas, Inc. and Eupraxia Pharmaceuticals Inc. are both Biotechnology companies. Arvinas, Inc. and Eupraxia Pharmaceuticals Inc. are of similar size ($537.8M and $509.4M). Eupraxia Pharmaceuticals Inc. has negative trailing earnings, so its P/E is not meaningful; Arvinas, Inc. trades at 58.3×. Arvinas, Inc. has the higher net margin (2.94% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Arvinas, Inc. leads on 7 and Eupraxia Pharmaceuticals Inc. on 5.

Valuation

Metric ARVN EPRX Biotechnology median
P/E 58.31 n/m 7.88
P/S 1.55 n/m 11.47
P/B 0.87 5.30 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 4.20 n/m 0.74
EV/Sales (0.24) n/m 10.73
Earnings yield 1.72% (12.73%) (28.84%)
Free cash flow yield (42.51%) (7.21%) (23.03%)

Profitability

Metric ARVN EPRX Biotechnology median
Gross margin 97.16% — 65.16%
Operating margin (5.72%) 0.00% 0.00%
Net margin 2.94% 0.00% 0.00%
Free cash flow margin (65.93%) 0.00% 0.00%
Return on equity 1.59% (117.82%) (57.72%)
Return on assets 1.17% (64.44%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARVN EPRX Biotechnology median
Revenue growth (TTM) (15.05%) — 5.64%
EPS growth (last fiscal year) 58.84% (35.53%) —
Revenue growth, 5-year CAGR 58.93% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ARVN EPRX Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 7.91 16.00 4.73
Net debt to EBITDA 5.62 2.11 0.96

Dividend

Metric ARVN EPRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ARVN EPRX Biotechnology median
Market cap 509.36m 537.83m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack